Mereo Q3 Loss Narrows to $5.9M; $26.1M Cash Funds Operations Into Late 2027
MREO sits 52% above its 52-week low of $0.2 on light trading volume (0.2× avg).
Summary
Mereo's Q3 2026 net loss narrowed to $5.9M from $7.0M, and management says $26.1M in cash lasts into late 2027 — excluding up to $40M it would receive if Sentynl exercises its alvelestat option. Setrusumab's regulatory path remains unresolved.
Key Events · Earnings and Guidance · MREO
-
Q3 Loss Narrows to $5.9M
Net loss for the third quarter of 2026 was $5.9M versus $7.0M a year earlier, driven by R&D falling to $2.1M from $4.3M and G&A to $4.9M from $6.0M.
-
Cash Falls to $26.1M
Cash and cash equivalents stood at $26.1M on September 30, 2026, down from $41.0M at December 31, 2025. Management expects this to fund operations into late 2027, excluding any Sentynl option or milestone payments.
-
Sentynl Option Worth Up to $40M
If Sentynl exercises its alvelestat option during the short option period, Mereo would receive $40M in upfront and R&D payments, plus eligibility for up to $435M in regulatory and commercial milestones and double-digit tiered royalties.
-
Setrusumab Path Still Unresolved
Mereo and Ultragenyx remain in regulatory discussions to determine whether a path forward exists for setrusumab in OI following the Orbit and Cosmic Phase 3 results; post-hoc fracture analyses were presented at ASBMR in October 2026.
Analysis · MREO · Life Sciences
The quarter's real story is the balance sheet, not the narrower loss. Cash fell to $26.1M from $41.0M at year-end 2025, and management says that funds operations only into late 2027. That runway excludes the up to $40M in upfront and R&D payments Mereo would collect if Sentynl exercises its alvelestat option, so survival past 2027 hinges on that option being exercised or on raising new capital. The net loss did improve to $5.9M from $7.0M a year ago as R&D and G&A spending were cut. Meanwhile setrusumab, the lead program, still has no agreed regulatory path with Ultragenyx after the failed Phase 3 studies, and the alvelestat Phase 3 trial is not expected to start until early 2027. This lands against a previously disclosed second Nasdaq delisting notice with a compliance deadline of February 16, 2027, so the clock is running on both listing and cash.
How filings like this one have moved
In the 30 days to Nov 9, 2026, 36.6% of the 2965 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MREO was trading at $0.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $48.4M. The 52-week trading range was $0.20 to $2.37. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.